Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (396)	11/9/2000 11:29:45 AM
From: tom pope	Read Replies (1) \| Respond to of 1833

The new math: 19.9/13.1 = .125

To: Joe Wesley who wrote (396)	11/9/2000 11:56:00 AM
From: RCMac	Respond to of 1833

""The entry of the order and the return of the $19.9 million will finally permit Cadus to focus on the future," said Russell Glass, President and Chief Executive Officer of Cadus. "This press release may contain forward-looking statements . . . . " If only it did actually "contain forward-looking statements." But looking only at the present, for anyone who’s come to the thread to see what today’s Press Release means: Adding back the $19.9 million to the $5.3 million in other cash on the books biz.yahoo.com means that KDUS has above $25 million in cash, or almost $2.00/share. Other thoughts on valuation are earlier in this thread, including: Message 14344049 And that’s just a static value-investors’ analysis. As to the value of KDUS's potential stream of future royalties, future licenses, etc. a review of Rick Harmon’s posts on this thread, including #359 Message 14630563 would be enlightening. --RCM